Amethyst and Stingray form Europe’s Largest oncology platform
Pan-European mid-market investment firm Fremman Capital has acquired Stingray Healthcare from Jacobs Capital to merge it with Amethyst Healthcare, creating Europe’s largest independent cancer care platform . The transaction unites two complementary oncology networks with a shared mission to expand access to high-quality, patient-centred radiotherapy services across Western and Central Europe. The merger leverages Amethyst’s established footprint in France, Poland,…
Genmab broadens late-stage portfolio with $8bn Merus acquisition
Copenhagen-based antibody therapeutics company Genmab has agreed to acquire Merus in a deal valuing the Dutch–U.S. oncology company at approximately $8bn. The move brings late-stage bispecific antibody petosemtamab into Genmab’s pipeline. Petosemtamab is in two Phase 3 trials for head and neck cancer, carries two FDA Breakthrough Therapy Designations, and could launch as early as 2027. According to Alcon’s management,…